The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as "polypeptides of the invention", and "immunoglobulin(s) of the invention", respectively). The invention also relates to constructs comprising such immunoglobulins, such as immunoglobulin single variable domains (ISVDs) or polypeptides as well as nucleic acids encoding such immunoglobulins or polypeptides (also referred to herein as "nucleic acid(s) of the invention"； to methods for preparing such immunoglobulins, polypeptides and constructs； to host cells expressing or capable of expressing such immunoglobulins or polypeptides； to compositions, and in particular to pharmaceutical compositions, that comprise such immunoglobulins, polypeptides, constructs, nucleic acids and/or host cells； and to uses of immunoglobulins, polypeptides, constructs, nucleic acids, host cells and/or compositions, in particular for prophylactic and/or therapeutic purposes, such as the prophylactic and/or therapeutic purposes mentioned herein. Other aspects, embodiments, advantages and applications of the invention will become clear from the further description herein.La présente invention concerne des polypeptides se liant à l'aggrécane ainsi qu'à ADAMTS5 et/ou MMP13, plus particulièrement des polypeptides qui comprennent ou consistent essentiellement en des immunoglobulines se liant à l'aggrécane, ainsi que des immunoglobulines liant l'ADAMTS5 et/ou des immunoglobulines liant MMP13 (également appelés "polypeptides de l'invention", et "immunoglobuline(s) de l'invention", respectivement). L'invention concerne également des constructions comprenant de telles immunoglobulines, telles que des domaines variables uniques d'immunoglobuline (ISVD) ou des polypeptides ainsi que des acides nucl
